Mercury Laboratories Limited Share Price

BSE: 538964

S Cap

₹ 785.30

-₹33.60 (-4.1%)

Last updated 12 Aug, 2026, 14:30 IST

Mercury Laboratories Limited Share Price Today

As of 12 Aug 2026, Mercury Laboratories Limited share price is ₹785.30. The stock opened at ₹790.00, compared to its previous close of ₹818.90. During today's trading session, Mercury Laboratories Limited share price moved in the range of ₹785.30 to ₹790.00, with an average price of ₹787.65 for the day. Looking at its last 52-week, the stock has touched a low of ₹620.55 and a high of ₹942.90.

₹785.30

4.10% down today

₹790.00

1D LOW

1D HIGH

Stock Performance

OutperformingBeat Nifty by 9.17 % in last 6 month

Mercury Laboratories Limited Returns Calculator

If you would've invested

₹

₹1,000₹1Cr

Historical Returns

1 Year

₹4,71,907-₹28,093 (-5.62%)

3 Year

₹4,90,813-₹9,188 (-1.84%)

5 Year

₹5,69,347+₹69,347 (+13.87%)

₹655.15₹982.65

Circuit Low

Circuit High

₹620.55₹942.90

52-Week Low

52-Week High

Circuit

₹655.15

₹982.65

52-week

₹620.55

₹942.90

About Mercury Laboratories Limited

ISIN

INE947G01011

Sector Market Cap

₹ 98.27 Cr

Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. It is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, and innovative products. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.

Mercury Laboratories Limited Financial Highlights

Revenue: Mercury Laboratories Limited reported revenue of ₹77.90 crore in FY26 vs ₹76.17 crore in FY25. It showed an increase of 2.27% on a yearly basis.
Operating Profit: Mercury Laboratories Limited reported an operating profit of ₹6.64 crore in FY26 vs ₹4.66 crore in FY25. It showed an increase of 42.49% on a year-on-year basis.
Net Profit: Mercury Laboratories Limited reported a net profit of ₹4.83 crore in FY26 vs ₹3.14 crore in FY25. It showed an increase of 53.82% on a yearly basis.

Mercury Laboratories Limited Quarterly Result Highlights

Mercury Laboratories Limited reported revenue of ₹16.01 crore in Jun 2026, compared with ₹21.11 crore in Mar 2026, representing a decrease of 24.16% on a quarter-on-quarter (QoQ) basis.
Mercury Laboratories Limited reported an operating profit of ₹0.39 crore in Jun 2026, compared with ₹1.74 crore in Mar 2026, representing a decrease of 77.59% on a quarter-on-quarter (QoQ) basis.
Mercury Laboratories Limited reported a profit of ₹0.30 crore in Jun 2026, compared with ₹1.23 crore in Mar 2026, reflecting a decrease of 75.61% on a QoQ basis.
The earnings per share (EPS) of Mercury Laboratories Limited stood at ₹26.21 during Jun 2026.

Know more

Promoters

73.66%

FII

0.00%

Other DII

0.00%

Retail and other

26.34%

Mutual funds

0.00%

Foreign institutions - FII

FII shareholding by period
Sep 2025	0.00%
Dec 2025	0.00%
Mar 2026	0.00%
Jun 2026	0.00%

Mkt Cap Cr

98.27

P/E

23.60

P/B

1.69

ROE

8.32%

D/E

0.15

ROCE

10.75%

Div. Yield

0.43%

EPS(TTM)

40.28

Turnover

0.93

EV/EBITDA

10.80

Net Margin

0.00%

Op. Margin

0.00%

ROA

5.27%

Quick Ratio

0.00

Curr. Ratio

4.37

Mkt Cap Cr

98.27

P/E

23.60

P/B

1.69

ROE

8.32%

D/E

0.15

ROCE

10.75%

Div. Yield

0.43%

EPS(TTM)

40.28

Turnover

0.93

EV/EBITDA

10.80

Net Margin

0.00%

Op. Margin

0.00%

ROA

5.27%

Quick Ratio

0.00

Curr. Ratio

4.37

Based on fundamentals, this stock's

Performance

Very Poor

Mercury Labs has not beaten FD return of 7%

Valuation

Overvalued

Mercury Labs appears overvalued compared to its peers

Peer Comparison

Peer comparison — key ratios
Name	Mkt Cap Cr	P/E	P/B	ROE	D/E	ROCE	Book Value	Div. Yield	Turnover	EPS(TTM)
Sun Pharmaceutical Industries	4,65,471.00	38.42	5.57	13.74%	0.61	17.33%	93.24	0.82%	0.48	10.90
Divis Laboratories	2,26,631.00	77.48	13.52	15.32%	0.00	19.56%	629.49	0.35%	0.55	98.19
Torrent Pharmaceuticals	1,85,157.00	85.88	22.02	25.49%	1.69	13.85%	222.76	0.69%	0.49	58.70
Cipla	1,18,107.00	35.19	3.43	11.27%	0.00	14.95%	423.36	0.89%	0.45	43.52
Zydus Lifesciences	1,17,705.00	25.63	4.34	18.59%	0.31	17.35%	237.30	0.09%	0.33	35.38
Lupin	1,04,158.00	18.76	4.64	23.76%	0.04	24.88%	659.05	0.79%	0.57	129.18
Laurus Labs	1,00,498.00	92.17	18.96	16.77%	0.40	16.14%	97.20	0.11%	0.67	13.72
Mankind Pharma	1,00,152.00	48.44	6.14	11.74%	0.34	13.13%	397.02	0.04%	0.44	49.37
Dr. Reddy's Laboratories	1,00,578.00	31.59	2.64	11.07%	0.18	12.54%	377.96	0.66%	0.41	38.68
Aurobindo Pharma	95,367.60	25.70	2.52	9.25%	0.19	11.76%	391.14	0.24%	0.38	41.58

Mercury Laboratories Limited Financials

Full statement

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Revenue	₹75.10	₹75.56	₹75.33	₹57.92
Other Income	₹1.07	₹1.09	₹1.72	₹0.82
Total Revenue	₹76.17	₹76.65	₹77.05	₹58.74
Total Expenses	₹71.51	₹69.73	₹69.61	₹53.83
Profit Before Tax	₹4.66	₹6.92	₹7.44	₹5.03
Tax	₹1.52	₹1.27	₹1.87	₹1.47
Profit After Tax	₹3.14	₹5.65	₹5.58	₹3.56
EPS - Basic	₹26.21	₹47.12	₹46.49	₹29.68
EPS - Diluted	₹26.21	₹47.12	₹46.49	₹29.68

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Profit before tax	₹4.66	₹6.92	₹7.44	₹5.03
Income before WC changes	₹8.14	₹10.12	₹10.29	₹7.91
Change in Assets	-₹5.77	₹0.40	-₹6.11	₹3.85
Change in Liabilities	₹4.03	-₹1.04	-₹0.63	-₹4.66
Change in WC	-₹1.75	-₹0.64	-₹6.73	-₹0.80
Cash flow from Operations	₹4.00	₹8.23	₹2.45	₹5.19
Cash flow from Investing	-₹9.04	-₹6.27	-₹1.06	-₹1.89
Cash flow from Financing	-₹0.99	-₹1.04	-₹1.01	-₹1.23
Total Cash Flow	-₹6.03	₹0.91	₹0.38	₹2.07
Cash (Start of the year)	₹8.23	₹7.32	₹6.93	₹4.87
Cash (End of the year)	₹2.19	₹8.23	₹7.32	₹6.93

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
Particulars	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Non-Current Assets	₹34.16	₹28.12	₹24.71	₹27.21
Current Assets	₹40.08	₹39.84	₹39.46	₹35.22
Total Assets	₹74.24	₹67.96	₹64.16	₹62.43
Current Liabilities	₹15.08	₹12.63	₹14.18	₹15.75
Net Current Asset	₹25.00	₹27.20	₹25.28	₹19.47
Non-Current Liabilities	₹5.59	₹4.49	₹4.36	₹6.38
Equity Capital	₹53.57	₹50.84	₹45.63	₹40.31
Total Equity & Liabilities	₹74.24	₹67.96	₹64.16	₹62.43